{"entity":{"id":"dendreon","kind":"company","name":"Dendreon","aka":["Dendreon Pharmaceuticals","Dendreon Corporation"],"tldr":"Dendreon makes sipuleucel-T (Provenge), the first autologous cellular immunotherapy approved for cancer, for metastatic prostate cancer; the company went bankrupt in 2014 and has been owned by China's Sanpower group since 2017.","summary":"Dendreon, now based in Seal Beach, California, developed sipuleucel-T (Provenge), an autologous cellular immunotherapy in which a patient's own antigen-presenting cells are activated against prostatic acid phosphatase and reinfused; it was approved by the FDA in 2010 for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after the IMPACT trial. High cost and slow uptake led the company into bankruptcy in 2014; Valeant bought the assets in 2015 and sold the business to the Sanpower Group in 2017, which continues to market Provenge in the United States. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.dendreon.com"},{"label":"ClinicalTrials.gov: trials led by Dendreon","url":"https://clinicaltrials.gov/search?lead=Dendreon"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Dendreon"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["cell-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["sipuleucel-t"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Seal Beach, CA","country":"US","companyType":"cell-therapy","website":"https://www.dendreon.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/dendreon/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/"}]}}